Samsung Bioepis' Keytruda biosimilar demonstrates equivalence in global Phase 3 trial
Samsung Bioepis said Monday that its proposed biosimilar SB27 demonstrated comparable efficacy and safety to Keytruda, a blockbuster cancer immunotherapy drug that was the world's best-selling pharmaceutical product last year, in a global Phase 3 clinical trial. According to the company, it announced the Phase 3 clinical study results at the Society for Immunotherapy of Cancer Annual Meeting 2026 held in Phoenix, Arizona from Nov. 4 to 8. Keytruda, developed by U.S. pharmaceutical company MSD, is a cancer immunotherapy drug that binds to programmed cell death protein 1 (PD-1), an immune checkpoint receptor, helping the immune system attack cancer cells. It was the world's best-selling drug last year, generating approximately 46 trillion won ($31.7 billion) in global sales. The Phase 3 study, which began in 2024, involved 555 patients with metastatic nonsquamous non-small cell lung cancer across 14 countries, comparing SB27 with the original drug in combination with standard chemotherapy. In the study, SB27 met its primary endpoint by demonstrating an equivalent objective response rate to
Read full articleMORE NEWS
U.S. Cleared Nvidia Chips to Chinese Firms With Empty Offices and Troubling Ties
The Commerce Department has approved dozens of Chinese companies to handle Nvidia’s H200 chips, some of which have ties to firms under sanctions over national security.
Why your next specialist visit could cost a lot more than expected
Already exorbitant fees are continuing to rise every year — here's by how much.
Former comic, lead instructor identified as Lake Elsinore skydivers killed in midair collision
Authorities have identified two skydivers who died Friday in Lake Elsinore while training to set a state record.
Woman fights for life after campfire set her clothes alight
She suffered significant burns and was rushed to hospital.
Woman fights for life after campfire set her clothes alight
She suffered significant burns and was rushed to hospital.
ANZ profit surges to $7.6b as cost-cutting drive pays off
ANZ’s bottom line benefited from a 14 per cent decline in operating expenses, while its operating income rose 3 per cent.
Hong Kong must retain the talent its world-class universities nurture
We can count on this administration to be quick to take credit. It took just one day for Chief Secretary Eric Chan Kwok-ki to claim credit on behalf of the Hong Kong government for the impressive results of the city’s universities in the latest Quacquarelli Symonds (QS) Asia University Rankings. All 11 of Hong Kong’s ranked institutions made it into Asia’s top 500 for the first time. Five of the 11 are ranked among Asia’s top 10. The University of Hong Kong took the crown as Asia’s top...
Sydney council considers controversial logo change
A council in Sydney's south is considering a proposal to remove Captain James Cook from its logo.
Pollock pulse check taunts Australia
England star Henry Pollock's pulse check try celebration taunts Australia at Twickenham.
Snow in parts of Victoria and NSW
A cold front has pushed snow across parts of NSW and Victoria, despite summer being just weeks away.
‘Am I normal?’ Inside the program for children who have sexually abused other children
New Street Services opened its doors in July 1998. Within an hour, they were so flooded with referrals they had to close their books. Now they are more necessary than ever.
Four killed in Egyptian train crash
At least four people have died and almost 90 others have been injured after two trains collided south of the Egyptian capital, Cairo.